Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS

Neurology

Volumn 53, Issue 7, 1999, Pages 1402-1408

  Trojano, M ^a   Avolio, C ^a   Liuzzi, G M ^a   Ruggieri, M ^a   Defazio, G ^a   Liguori, M ^a   Santacroce, M P ^a   Paolicelli, D ^a   Giuliani, F ^a   Riccio, P ^b   Livrea, P ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Matrix metalloproteinases; MS; rIFN 1b; Soluble ICAM 1

Indexed keywords

GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RELAPSE;

EID: 0032716573     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1402     Document Type: Article

References (46)

1. Stone LA, Frank JA, Albert PS, et al. The effects of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
2. Jacobs LD, the Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. Defazio G, Trojano M, Ribatti D, et al. Expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon β-1a and TNFα. J Neuroimmunol 1998;88:11-30.
5. Miller A, Lanir N, Shapiro S, et al. Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis and other autoimmune diseases. J Neuroimmunol 1996;64:151-161.
6. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997;49:1111-1116.
7. Soilu-Hanninen, Salmi A, Salonen R. Interferon-β downregulates expression of VLA-4 antigen and antagonized interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 1995;60:99-106.
8. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
9. Stuve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
10. Stuve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997;80:38-46.
11. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-674.
12. Washington R, Burton J, Todd RF III, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994;35:89-97.
13. Cannella B, Cross AH, Raine CS. Adhesion-related molecules in the central nervous system: upregulation correlates with inflammatory influx during relapsing autoimmune encephalomyelitis. Lab Invest 1991;1:23-31.
14. Archelos JJ, Jung S, Maurer M, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993;34: 145-154.
15. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen-activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-1204.
16. Clements JM, Cossins JA, Wells GMA, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-alpha inhibitor. J Neuroimmunol 1997;74:85-94.
17. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflam Res 1995;44:345-349.
18. Norga K, Paemen L, Masure S, et al. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine model of multiple sclerosis by the protease inhibitor D-penicillamine. Inflam Res 1995;44:529-534.
19. Trojano M, Avolio C, Simone IL, et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging enhancement and cerebrospinal fluid findings. Neurology 1996;47:1535-1541.
20. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-333.
21. Giovannoni G, Lai M, Thorpe J, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997;48:1557-1565.
22. McDonnell GV, McMillan SA, Douglas JP, Droogan AG, Hawkins SA. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. J Neuroimmunol 1998;85:186-192.
23. Rieckmann P, Michel U, Albrecht M, Bruck W, Wockel L, Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 1995;60:9-15.
24. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
25. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-2334.
26. Rosemberg GA, Deneoff JE, Correa Jr N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
27. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann Neurol 1983;13:227-231.
28. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58:300-306.
29. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-676.
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
31. Liu C, Li Wan Po A, Blumhardt L. "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:726-729.
32. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102:196-202.
33. Masure S, Billiau A, Van Damme J, Opdenakker G. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim Biophys Acta 1990; 1054:317-325.
34. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFN-beta-1b: the use of an assay for neutralizing antibodies (NAB). Neurology 1996;47:865-866.
35. Kallmann BA, Hummel V, Rieckmann P. Human cerebral endothelial cells are a major source of soluble cellular adhesion molecules during inflammatory conditions. Neurology 1998;50:A111. Abstract.
36. Rothlein R, Mainolfi EA, CzaijkowskiM, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991;147: 3788-3793.
37. Lyons PD, Benveniste EN. Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia 1998;22:103-112.
38. Rokhlin OW, Cohen MB. Soluble form of CD44 and CD54 (ICAM-1) cellular adhesion molecules are released by human prostatic cancer cell lines. Cancer Lett 1996;107:29-35.
39. King PD, Sandberg ET, Selvakumar A, Fang P, Beaudet AL, Dupont B. Novel isoforms of murine intercellular adhesion molecule-1 generate by alternate RNA splicing. J Immunol 1995;154:6080-6093.
40. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999;94:1-14.
41. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-166.
42. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997;158: 2327-2333.
43. Mackay AR, Ballin M, Pelina MD, et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992;12:168-184.
44. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990;265:11077-11082.
45. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223-226.
46. Rudick RA, Simonian NA, Alam, JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.